The EVI5L Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Burkitt’s lymphoma Raji B lymphocyte line. This product features targeted disruption of the EVI5L gene, providing a loss-of-function model to study EVI5L-dependent cellular processes. The polyclonal population comprises a heterogeneous pool of edited alleles, reflecting the diversity of CRISPR-mediated gene disruption, and is well-suited for bulk functional analyses.
Raji cells are a suspension B lymphocyte line established from a Burkitt’s lymphoma patient. They are Epstein-Barr virus (EBV) positive and maintain key characteristics of mature B cells, making them a standard model for B-cell malignancies, immunological studies, and drug screening. Their robust growth and stable karyotype support reproducible investigations into cell cycle regulation, apoptosis, and membrane trafficking.
EVI5L encodes a Rab GTPase-activating protein (GAP) that stimulates GTP hydrolysis on Rab35, a central regulator of endocytic recycling and cytokinesis. Through inactivation of Rab35, EVI5L controls membrane trafficking via the endosomal system and is functionally coupled to the exocyst complex and actin cytoskeleton regulators. It directly interacts with Rab35, exocyst components, and TBC1D10A-C family proteins, and its activity is influenced by upstream cell cycle regulators and receptor tyrosine kinases. Consequently, EVI5L integrates signals governing membrane dynamics, cell division, and exosome secretion.
In Raji B lymphoma cells, disruption of EVI5L impairs Rab35-dependent endocytic recycling, which can lead to defective cytokinesis and altered exosome release. Given Rab35??s role in actin remodeling and exocyst function, EVI5L knockout may cause abscission failure, cell cycle delays, and changes in intercellular communication through exosomes. These phenotypes are particularly relevant to lymphoma biology, where aberrant trafficking and signaling can influence tumor progression and drug sensitivity.
This polyclonal knockout product is suited for investigating Rab35-mediated trafficking in B cell lymphoma, EVI5L function in cytokinesis, exosome biogenesis, and drug resistance mechanisms. Typical assays include Rab35 GTPase activity measurements, immunofluorescence for abscission defects, flow cytometry cell cycle analysis, Western blotting for EVI5L and Rab35, transferrin uptake assays, exosome isolation, and cell viability testing. These cells provide a lymphoma-relevant platform for dissecting EVI5L??s roles in normal and pathological B-cell biology. For additional information or technical support, please contact Ascent Research.
